Skip to main content

  • An updated meta-analysis of TAVR in patients at intermediate risk for SAVR

    • Posted: 02/11/2019
    • Author:

      Mohamad Lazkani, MD; Nirmal Singh, MD; Carol Howe, MD; Nachiket Patel, MD; Modesto J. Colón, mD; Mark Tasset, MD; Orazio Amabile, MD; Michael Morris, MD; H. Kenith Fang, MD; Ashish Pershad, MD

    • 2019News ArticlesCRM

    Abstract

    Background

    Transcatheter aortic valve replacement (TAVR) has been approved for use in patients with severe aortic stenosis at intermediate, high and extreme surgical risk. This meta-analysis was performed to assess the safety and efficacy of TAVR compared to surgical aortic valve replacement (SAVR) in intermediate risk patients.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details